Committee sessions
Plenary lectures
Main Symposia
Research group sessions
Special sessions
Sponsored sessions
Corporate symposia
| CS1 Diabetes and metabolism journal session : Best papers at DMJ 2021 |
14:00~15:00 / Friday 7 October Diamond Hall, 3F Chairman:Kyung Mook Choi, Won-Young Lee |
Overview |
|---|---|---|
| Diabetes and Metabolism Journal (dmj) is the official journal of the Korean Diabetes Association (KDA) and the 2021 impact factor of dmj is 5.893. This session consists of a time to share the research contents of five excellent papers carefully selected through the fair review process of the publication committee among the original articles published in 2021. We cordially ask for your continued support for dmj's development in the future. | ||
|
CS1-1Diabetes mellitus and cause-specific mortality: a population-based study | |
|
CS1-2Time to reach target HbA1c is associated with long-term durable glycemic control and risk of diabetic complications in patients with newly diagnosed type 2 diabetes: a 6-year observational study | |
|
CS1-3Ipragliflozin, an SGLT2 inhibitor, ameliorates high-fat diet-induced metabolic changes by upregulating energy expenditure through activation of the AMPK/SIRT1 pathway | |
|
CS1-4Magnetic resonance-based assessments better capture pathophysiologic profiles and progression in nonalcoholic fatty liver disease | |
|
CS1-5Effect of sarcopenia and body shape on cardiovascular disease according to obesity phenotypes | |
|
CS1-6The effects of exercise and restriction of sugar-sweetened beverages on muscle function and autophagy regulation in high-fat high-sucrose-fed obesity mice | |
| CS2 Committee of clinical practice guideline session (K) : Initial treatment strategy in patients with newly diagnosed type 2 diabetes mellitus |
16:00~18:00 / Friday 7 October Emerald Hall B, 3F Chairman:Kyung Soo Ko, Min Kyong Moon |
Overview |
|---|---|---|
| Type 2 diabetes is a progressive disorder characterized by increasing hyperglycemia and the need to gradually intensify therapy in order to achieve and maintain glycemic control. Until now, sequential therapy, starting with metformin monotherapy and adding drugs one by one, has been recommended as the standard treatment. However, early initiation of combination therapy has been proposed as an approach to achieve glycemic goals earlier and delay the deterioration of glycemic control and with possible better preservation of β-cell function. In this session, we will discuss the effectiveness of various treatment strategies to achieve and maintain glycemic control in patients with newly diagnosed type 2 diabetes and explore tailored treatment strategies considering individual characteristics. | ||
|
CS2-1Nonpharmacological therapy vs. pharmacological therapy | |
|
CS2-2Metformin monotherapy vs. initial combination therapy | |
|
CS2-3Insulin-based vs. oral combination therapy | |
|
CS2-4Treatment strategies based on the sub-classification of adult-onset diabetes mellitus | |
|
CS2-Panel 1Panel discussion | |
|
CS2-Panel 2Panel discussion | |
|
CS2-Panel 3Panel discussion | |
|
CS2-Panel 4Panel discussion | |
후원
| CS3 Committee of media-public relation session (K) : Fact sheets on cardiometabolic diseases in Korea: current status and prospects |
16:00~18:00 / Friday 7 October Diamond Hall, 3F Chairman:Seihyun Baik, Eun Gyoung Hong |
Overview |
|---|---|---|
| Professional societies have published fact sheets to provide representative national statistics on cardiometabolic diseases such as diabetes, hypertension, dyslipidemia, and obesity. In Korea, the Korea Disease Control and Prevention Agency and the National Health Insurance Service have provided publicly available health big data on noncommunicable diseases. In this session, we will invite experts in this field and discuss various issues that arise from developing fact sheets using national statistical data. | ||
|
CS3-1Diabetes fact sheet in Korea | |
|
CS3-2Korea hypertension fact sheet | |
|
CS3-3Dyslipidemia fact sheet in Korea | |
|
CS3-4Obesity fact sheet | |
|
CS3-5Noncommunicable diseases (NCD) statistics based on Korea National Health and Nutrition Examination Survey (KNHANES) | |
|
CS3-6National statistics of NCD using the NHIS database | |
|
CS3-Panel 1Panel discussion | |
|
CS3-Panel 2Panel discussion | |
| CS4 Committee of the health insurance and legislation session (K) : Strengthening of medical insurance coverage for type 1 diabetes mellitus - severe incurable disease registration |
16:00~18:00 / Friday 7 October Flamingo, Hotel, 2F Chairman:Young Sun Hong, Chong Hwa Kim |
Overview |
|---|---|---|
| The Korean government designates and manages Severe Incurable Diseases that, if not adequately treated, can be fatal or cause permanent disability. Patients with Severe Incurable Diseases receive financial support from National Health Insurance Service to help with catastrophic medical expenses. Type 1 diabetes is an endocrine metabolic disease that accompanies permanent damage to the pancreas. Although permanent insulin treatment is required, it is not designated as a Severe Incurable Disease, so type 1 diabetes patients and their families suffer from high medical costs. In this session, we would like to learn about registration as Severe Incurable Diseases in Korea and discuss the necessity of designating type 1 diabetes as a Severe Incurable Diseases. | ||
|
CS4-1Overview of special estimate cases system of incurable diseases | |
|
CS4-2Type 1 diabetes mellitus - why it should be treated as a severe incurable diseases | |
|
CS4-Panel 1Panel discussion | |
|
CS4-Panel 2TBD | |
|
CS4-Panel 3Panel discussion | |
|
CS4-Panel 4Panel discussion | |
|
CS4-Panel 5Panel discussion | |
|
CS4-Panel 6Panel discussion | |
| CS5 Committee of international liaison session : SGLT2i and kidney |
09:00~11:00 / Saturday 8 October Emerald Hall A, 3F Chairman:Sung Rae Kim, Sung Hee Choi |
Overview |
|---|---|---|
| Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of chronic kidney disease (CKD) is an important treatment goal in the management of T2DM. In addition to cardiovascular benefit, recent renal outcome trials of SGLT2i showed profound reno-protective effects. Therefore, this session will summarize the current recommendation of SGLT2i in clinical practice guidelines. We invited two international speakers to review the cardiometabolic renal axis beyond glucose lowering effect of SGLT2i and nephrologist’s view of SGLT2i and CKD in Asians. This session will update your view on SGLT2i and Kidney. | ||
|
CS5-1The current recommendation of SGLT2 inhibitor in clinical practice guidelines | |
|
CS5-2Nephrologist’s view of sodium-glucose co-transporter-2 inhibitors and chronic kidney disease (in Asians) | |
|
CS5-3SGLT2 inhibitor: beyond glucose lowering effect, cardiometabolic renal axis | |
|
CS5-Panel 1Panel discussion | |
|
CS5-Panel 2Panel discussion | |
|
CS5-Panel 3Panel discussion | |
